Biotech Values

[DewDiligence]

The full detailed presentation of ABBV/ENTA’s six phase-3 HCV trials for the initial NDA (the first six trials listed in #msg-93647264) is planned for EASL in Apr 2014, according to ABBV’s CS webcast today. Top-line data from these trials will be released as the data become available, starting with SAPHIRE-1 and SAPHIRE-2 before 2013 year-end.

EASL 2014 webpage: http://www.easl.eu/_events/the-international-liver-congress/the-international-liver-congress-2014-49th-annual-meeting-of-the-european-association-for-the-study-of-the-liver .